Replies to post #171028 on Amarin Corp Plc (AMRN)

[Biobillionair]

As I stated in a prior post regarding Vascepa target population:

Population which could potentially benefit from Vascepa is large
? >25% of adults in U.S. have CV risk factors beyond LDL-C (e.g. ~50M to 70M
adults in U.S. alone have elevated triglycerides levels >150 mg/dL)
? Many of these patients are already on statin therapy

Cardiovascular prevention population is greater than 70 million. The R-I trial studied the elevated trig > 150 mg/dL population which is about 50-70 million adults in US, the prevention population captures more than the trig market. Vascepa is NOT A TRIG DRUG IT'S A CVD PREVENTION DRUG!!!

Additional market penetration numbers:

? Much room to grow: Vascepa market share H1’18 was ~5% of the <4% Rx use

This above PATHETIC penetration number is directly due to the piss poor regulatory scheme Amarin and Vascepa have been exposed to.





BB